Compare DLXY & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DLXY | AIMD |
|---|---|---|
| Founded | 2007 | 1984 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 10.2M |
| IPO Year | 2025 | N/A |
| Metric | DLXY | AIMD |
|---|---|---|
| Price | $0.88 | $1.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 55.0K | 24.2K |
| Earning Date | 12-30-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1077.13 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $273,155,000.00 | $113,037.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.56 | ★ N/A |
| Revenue Growth | N/A | ★ 178.19 |
| 52 Week Low | $0.61 | $1.61 |
| 52 Week High | $7.16 | $5.00 |
| Indicator | DLXY | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 40.61 |
| Support Level | N/A | $1.74 |
| Resistance Level | N/A | $1.96 |
| Average True Range (ATR) | 0.00 | 0.12 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 42.11 |
Delixy Holdings Ltd a holding company that operates through subsidiary. It is engaged in the trading of oil-related products, which can be categorized into crude oil, and oil-based products such as naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. The company has two reportable segments: the Sale of crude oil and the Sale of oil-based products. Key revenue is generated from the Sale of crude oil.
Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.